Supriya Lifesciences to raise INR 1200 crore from its IPO on December 16, 2021; has chosen Lifescience Intellipedia as one of its data sourcing partners for its DHRP

Supriya Lifesciences to raise INR 1200 crore from its IPO on December 16, 2021; has chosen Lifescience Intellipedia as one of its data sourcing partners for its DHRP

By, Admin 15 December 2021

On December 16, 2021, Supriya Lifescience Limited to launch its initial public offer (IPO) which will be closed by December 20, 2021. While preparing its DRHP (Draft Red Herring Prospectus) Supriya Lifesciences collaborated with CRISIL and Lifescience Intellipedia. The Lifescience Intellipedia was one of the data sourcing partner which has provided several data points related to the market details of the products which are there in Supriya Lifesciences portfolio. Supriya Lifesciences produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Supriya Lifesciences enjoys being the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. It is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume. More details are provided in the DHRP filed available at the link below. DHRP Link: https://www.sebi.gov.in/filings/public-issues/may-2021/supriya-lifescience-limited_50137.html Description: Chart Description automatically generated Pic 1: Sample Data Excerpts from DHRP data point IPO Details: The offer price range has been set at Rs 265 to Rs 274 per equity share. Bids can be placed for as few as 54 stock shares and as many as 54 equity shares after that. The company intends to raise up to Rs. 7000 million in funding. The offer consists of a fresh issue of equity shares by the company worth up to Rs. 2,000 million (the "Fresh Issue") and an offer for sale by Satish Waman Wagh for up to Rs. 5,000 million. This Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!